Acemini medical insurance reimbursement status and purchase price analysis

Aximini, this professional third-generation tyrosine kinase inhibitor (TKI), is gradually becoming a new star in the treatment of chronic myelogenous leukemia (CML). Its unique mechanism of action is to inhibit the "myristoyl" pocket of ABL1kinase, making it excellent in controlling the activity of BCR-ABL fusion genes. Especially for those patients who are resistant to first- and second-generation TKI drugs, especially those carrying the T315I mutation, aceminib has brought significant efficacy.

However, Acemini is not currently available in China, which means that patients cannot directly purchase the drug in domestic pharmacies or hospitals. At the same time, it has not yet been included in the domestic medical insurance directory. Therefore, for domestic patients who want to use aximini, they usually need to obtain it through overseas drug purchase channels.

In the overseas market, the original drug of Asiminib is mainly produced by European pharmaceutical companies, and its price is quite high. The price of each box is usually around tens of thousands of yuan, which undoubtedly puts huge financial pressure on patients. For patients who cannot afford the high prices of brand-name drugs, generic drugs in Laos have become an affordable option. The ingredients of generic drugs in Laos are basically the same as those of original drugs, and they also have excellent therapeutic effects. The price per box is about more than 4,000 yuan.

Since Acemini has not yet been launched in the country, the issue of medical insurance reimbursement cannot yet be resolved. Patients need to pay out of pocket when purchasing drugs, or reduce their financial burden through social donations, charity projects, etc. In the future, with the introduction of Acemini in China, patients expect it to be included in the medical insurance catalog as soon as possible, thereby providing more patients with affordable treatment options.